Atrium Therapeutics Inc RNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Atrium Therapeutics Reports Third Quarter 2026 Financial Results
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive Financing
Atrium Therapeutics Announces $50 Million Private Placement
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $6.48
- Day Range
- $6.45–6.78
- 52-Week Range
- $6.36–16.77
- Bid/Ask
- $6.67 / $6.70
- Shares Outstanding
- 21.57M
- Market Cap
- $143.88M
- Volume/Avg
- 121,824 / 293,101
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- —
Valuation
Metric | RNA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.52 |
Price/Sales | 2.85 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RNA |
|---|---|
Quick Ratio | 10.02 |
Current Ratio | 10.46 |
Interest Coverage | — |
Quick Ratio
RNA
Profitability
Metric | RNA |
|---|---|
Return on Assets (Normalized) | −30.20% |
Return on Equity (Normalized) | −39.16% |
Return on Invested Capital (Normalized) | −38.69% |
Return on Assets
RNA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|t&?!!N# | LOCK|P>pj | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#HN<&!m | LOCK|Hj<C# | $99B | |||
| Moderna Inc MRNA | LOCK|Cq!JT? | LOCK|D@G | $84B | |||
| argenx SE ADR ARGX | LOCK|b&><np> | LOCK|!r! | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|C?>#rK | LOCK|K? | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|B&M%NDQn | LOCK|^M!& | $31B | |||
| Incyte Corp INCY | LOCK|Qm%wRL | LOCK|c^ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|Vn$S$s | LOCK|lH& | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^vd$ssj | LOCK|Z!%s | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&#B@n? | LOCK|ks? | $15B |